Orlando, Florida (ots/PRNewswire) - Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE) study comparing the ...
Orlando, Florida (ots/PRNewswire) - Poster Presentation #1083-P Ozempic® (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass index (BMI), with the greatest reductions occurring in adults ...
Orlando, Florida (ots/PRNewswire) - Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to findings from the PIONEER 1 phase 3a trial. The trial evaluated the efficacy and safety of ...
Orlando, Florida (ots/PRNewswire) - Abstract #620 Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight with once-weekly semaglutide treatment compared to sitagliptin, exenatide extended release (ER) and insulin glargine U100 in adults with ...
Ballerup, Denmark and Orlando, Florida (ots/PRNewswire) - LEO Pharma today announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema. Tralokinumab is an investigational ...
Orlando, Florida (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstract #290 Findings from a phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment ...